Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 May 15;2(10):1101–1114. doi: 10.1182/bloodadvances.2017015404

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 by The American Society of Hematology

PMC Copyright notice

Figure 7. — Resolution of the CD56^negCD16^possubset from eBL children after chemotherapy. NK cell subsets were defined by CD56 and CD16 expression. The first time point was before chemotherapy, and the second and third time points were 3 and 9 months, respectively, after diagnosis (during remission). (A) Changes in the percentage of NK cells were defined as the number of NK cells (CD56^pos and/or CD16^pos)/total number of live lymphocytes. (B) Changes in the percentage of CD56^negCD16^pos NK cells at each time point for 2 eBL patients. (C) Cytograms for the 3 time points for patient “BL1.” Changes in activation (D) and NCR (E) markers over time for both eBL children (“BL1” and “BL2”) for CD56^negCD16^pos NK cells. (F) Plots of NKp30/NKp46, NKp30/2B4, and NKp46/2B4 coexpression for CD56^negCD16^pos NK cells from an eBL1 patient during the course of treatment, as well as for 3 healthy Nandi children.